lmidafenacin is primarily metabolized by CYP3A4 and UGT1A4 in the liver. lmidafenacin (Uritos®) should be administered with care when co-administered with the following drugs.
| Drugs | Signs, Symptoms, and Treatment | Mechanism and Risk Factors |
| Drug Inhibiting CYP3A4: Itraconazole erythromycin clarithromycin , etc. | When this product was co-administered with itraconazole to healthy adult males, Cmax and AUC of the product increased to about 1.3 and 1.8 times those of monotherapy, respectively. | Since this product is primarily metabolized by CYP3A4, metabolism of this product is inhibited by these drugs. |
| Anticholinergic agents Antihistaminic agents , Tricyclic antidepressants Phenothiazines Monoamine oxidase inhibitors | Symptoms including thirst/dry mouth, constipation, and dysuria may occur potently. | The anticholinergic effect of this product may be enhanced by these drugs. |